Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nls Pharmaceutics Ltd (NLSP)

Nls Pharmaceutics Ltd (NLSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,963
  • Shares Outstanding, K 3,815
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,170 K
  • EBIT $ 0 M
  • EBITDA $ -12 M
  • 60-Month Beta -0.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.30

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.00 +9.00%
on 11/15/24
4.74 -31.01%
on 11/04/24
-0.91 (-21.77%)
since 10/25/24
3-Month
3.00 +9.00%
on 11/15/24
7.16 -54.36%
on 08/28/24
-3.65 (-52.75%)
since 08/27/24
52-Week
3.00 +9.00%
on 11/15/24
29.08 -88.76%
on 12/01/23
-12.27 (-78.96%)
since 11/27/23

Most Recent Stories

More News
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / November 4, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company, and Kadimastem Ltd. (TASE: KDST.TA") ("Kadimastem"),...

NLSP : 3.27 (-10.66%)
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

ZURICH, SWITZERLAND / ACCESSWIRE / October 21, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to developing...

NLSPW : 0.0104 (+15.56%)
NLSP : 3.27 (-10.66%)
NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy...

NLSP : 3.27 (-10.66%)
NLS Pharmaceutics Announces Registered Direct Offering

ZURICH, SWITZERLAND / ACCESSWIRE / June 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

NLSP : 3.27 (-10.66%)
NLSPW : 0.0104 (+15.56%)
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements

ZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a leading Swiss biopharmaceutical company dedicated to pioneering therapies...

NLSP : 3.27 (-10.66%)
NLSPW : 0.0104 (+15.56%)
NLS Pharmaceutics CEO Issues Letter to Shareholders

ZURICH, SWITZERLAND / ACCESSWIRE / August 28, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...

NLSP : 3.27 (-10.66%)
NLSPW : 0.0104 (+15.56%)
NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy

ZURICH, SWITZERLAND / ACCESSWIRE / May 2, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development...

NLSPW : 0.0104 (+15.56%)
NLSP : 3.27 (-10.66%)
Why Did Bullfrog AI Stock Jump More Than 50%?

Trading volume and share price for BFRG took significant leaps forward on news the digital biopharmaceutical company will partner with Johns Hopkins University.

BFRG : 2.14 (+0.47%)
SHPH : 0.8500 (-2.30%)
FREQ : 14.9800 (+5.94%)
NLSP : 3.27 (-10.66%)
NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2

ZURICH, SWITZERLAND / ACCESSWIRE / March 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development...

NLSPW : 0.0104 (+15.56%)
NLSP : 3.27 (-10.66%)
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia

ZURICH, SWITZERLAND / ACCESSWIRE / July 21, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

NLSP : 3.27 (-10.66%)
NLSPW : 0.0104 (+15.56%)

Business Summary

NLS Pharmaceutics Ltd. is a clinical-stage pharmaceutical company. It is focused on the discovery and development of therapies for rare and complex central nervous system disorders. The company's principal product candidate includes Quilience(R). NLS Pharmaceutics Ltd. is based in Switzerland.

See More

Key Turning Points

3rd Resistance Point 3.84
2nd Resistance Point 3.71
1st Resistance Point 3.49
Last Price 3.27
1st Support Level 3.14
2nd Support Level 3.01
3rd Support Level 2.79

See More

52-Week High 29.08
Fibonacci 61.8% 19.12
Fibonacci 50% 16.04
Fibonacci 38.2% 12.96
Last Price 3.27
52-Week Low 3.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar